Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01591902 · ClinicalTrials.gov registry record · Phase 4
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
A Phase 4 study, sponsored by Theratechnologies.
- Terminated
- Registry status
- Phase 4
- Development phase
- 129
- Enrollment target
NCT01591902 is a Phase 4 study that was terminated before completion, run by Theratechnologies. The registered enrollment target is 129 participants.
The verdict
NCT01591902, a Phase 4 study, was terminated before completion, sponsored by Theratechnologies.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 129 participants
- Enrollment target
Study Summary
To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Tesamorelin
- DRUG Placebo-Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2012-06 |
| Est. Completion | 2018-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01591902
The ClinicalTrials.gov registry entry for NCT01591902 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theratechnologies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tesamorelin is the first listed.
NCT01591902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01591902 about?
NCT01591902 is a clinical study titled "Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®". To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT01591902?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 129 participants. The study started on 2012-06. Estimated completion is 2018-08.
What interventions are being tested in trial NCT01591902?
The interventions under investigation include: Tesamorelin (DRUG), Placebo-Control (DRUG).
Who is sponsoring clinical trial NCT01591902?
This trial is sponsored by Theratechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.